|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.222 SEK | -1.77% |
|
-2.71% | -37.97% |
| 05-06 | IRLAB Q1 operating result swings to profit of SEK 10.7 mln | RE |
| 05-06 | Irlab reports growth in revenue and operating profit | FW |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -19.77 | 7.8 | -17.59 | -44.96 | -29.11 | |||||
Return on Total Capital | -21.28 | 8.68 | -19.98 | -51.38 | -38.59 | |||||
Return On Equity % | -34.61 | 13.86 | -32.86 | -87.48 | -112.03 | |||||
Return on Common Equity | -34.61 | 13.86 | -32.86 | -87.48 | -112.03 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | -21.78K | 60.66 | -105.94 | -2.16K | -44.03 | |||||
SG&A Margin | 7.99K | 14.93 | 69.49 | 934.87 | 48.8 | |||||
EBITDA Margin % | -30.38K | 25.54 | -182 | -3.16K | -76.17 | |||||
EBITA Margin % | -30.49K | 25.3 | -183.2 | -3.17K | -77.11 | |||||
EBIT Margin % | -30.49K | 25.3 | -183.2 | -3.17K | -77.11 | |||||
Income From Continuing Operations Margin % | -30.55K | 24.92 | -185.5 | -3.13K | -87.85 | |||||
Net Income Margin % | -30.55K | 24.92 | -185.5 | -3.13K | -87.85 | |||||
Net Avail. For Common Margin % | -30.55K | 24.92 | -185.5 | -3.13K | -87.85 | |||||
Normalized Net Income Margin | -19.09K | 15.58 | -115.94 | -1.96K | -54.91 | |||||
Levered Free Cash Flow Margin | -18.41K | 33.54 | -169.4 | -1.76K | -40.97 | |||||
Unlevered Free Cash Flow Margin | -18.37K | 33.65 | -169.1 | -1.76K | -34.05 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0 | 0.49 | 0.15 | 0.02 | 0.6 | |||||
Fixed Assets Turnover | 0.06 | 32.81 | 7.47 | 0.77 | 11.49 | |||||
Receivables Turnover (Average Receivables) | - | - | 15.69 | - | - | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 13.56 | 6.07 | 8.31 | 3.36 | 0.8 | |||||
Quick Ratio | 13.47 | 5.95 | 8.19 | 3.28 | 0.77 | |||||
Operating Cash Flow to Current Liabilities | -4.26 | 1.85 | -4.41 | -4.49 | -0.66 | |||||
Days Sales Outstanding (Average Receivables) | - | - | 23.26 | - | - | |||||
Average Days Payable Outstanding | 33.8 | 35.69 | 32.37 | 29.21 | 27.48 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 0.84 | 1.65 | 1.37 | 23.81 | 185.14 | |||||
Total Debt / Total Capital | 0.83 | 1.63 | 1.35 | 19.23 | 64.93 | |||||
LT Debt/Equity | 0.36 | 0.89 | 0.13 | 21.27 | 10.83 | |||||
Long-Term Debt / Total Capital | 0.36 | 0.88 | 0.13 | 17.18 | 3.8 | |||||
Total Liabilities / Total Assets | 6 | 15.44 | 10.11 | 34.64 | 76.04 | |||||
EBIT / Interest Expense | -469.02 | 142.1 | -377.11 | -904.97 | -6.96 | |||||
EBITDA / Interest Expense | -458.77 | 150.79 | -364.58 | -883.29 | -6.53 | |||||
(EBITDA - Capex) / Interest Expense | -460.79 | 148.87 | -374.26 | -884.76 | -6.55 | |||||
Total Debt / EBITDA | -0.03 | 0.12 | -0.04 | -0.16 | -0.88 | |||||
Net Debt / EBITDA | 3.06 | -7.09 | 2.3 | 0.48 | 0.09 | |||||
Total Debt / (EBITDA - Capex) | -0.03 | 0.12 | -0.04 | -0.16 | -0.88 | |||||
Net Debt / (EBITDA - Capex) | 3.05 | -7.18 | 2.24 | 0.48 | 0.09 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -19.35 | 69.16K | -70.58 | -90.71 | 1.57K | |||||
Gross Profit, 1 Yr. Growth % | -7.71 | -292.94 | -151.39 | 89.49 | -66.06 | |||||
EBITDA, 1 Yr. Growth % | -3.99 | -158.17 | -309.66 | 61.03 | -59.77 | |||||
EBITA, 1 Yr. Growth % | -3.91 | -157.42 | -313.03 | 60.79 | -59.48 | |||||
EBIT, 1 Yr. Growth % | -3.91 | -157.42 | -313.03 | 60.79 | -59.48 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -4.65 | -156.5 | -319.01 | 56.82 | -53.26 | |||||
Net Income, 1 Yr. Growth % | -4.65 | -156.5 | -319.01 | 56.82 | -53.26 | |||||
Normalized Net Income, 1 Yr. Growth % | -3.98 | -156.5 | -319.01 | 56.82 | -53.26 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -18.82 | -152.02 | -318.8 | 56.71 | -53.27 | |||||
Accounts Receivable, 1 Yr. Growth % | - | - | -25.68 | - | - | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -27.07 | 93.4 | -4.06 | -16.7 | 46.78 | |||||
Total Assets, 1 Yr. Growth % | 77.86 | 27.67 | -31.52 | -45.26 | -23.1 | |||||
Tangible Book Value, 1 Yr. Growth % | 165.5 | 34.04 | -31.68 | -71.76 | -120.65 | |||||
Common Equity, 1 Yr. Growth % | 91.32 | 14.83 | -27.2 | -60.2 | -71.81 | |||||
Cash From Operations, 1 Yr. Growth % | -2.18 | -244.19 | -210.86 | 15.59 | -60.21 | |||||
Capital Expenditures, 1 Yr. Growth % | 187.59 | 79.7 | 306.21 | -89.81 | -32.08 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 6.86 | -226.02 | -248.61 | -3.46 | -61.23 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 6.98 | -226.71 | -247.85 | -3.41 | -67.74 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 23.72 | 2.26K | 1.33K | -83.47 | 24.41 | |||||
Gross Profit, 2 Yr. CAGR % | 9.92 | 33.44 | -0.43 | -1.32 | -19.8 | |||||
EBITDA, 2 Yr. CAGR % | 11.86 | -25.22 | 10.44 | 83.74 | -19.52 | |||||
EBITA, 2 Yr. CAGR % | 11.81 | -25.68 | 10.6 | 85.08 | -19.29 | |||||
EBIT, 2 Yr. CAGR % | 11.81 | -25.68 | 10.6 | 85.08 | -19.29 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 11.22 | -26.6 | 11.24 | 85.32 | -14.38 | |||||
Net Income, 2 Yr. CAGR % | 11.22 | -26.6 | 11.24 | 85.32 | -14.38 | |||||
Normalized Net Income, 2 Yr. CAGR % | 11.78 | -26.35 | 11.24 | 85.32 | -14.38 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -0.4 | -35.01 | 6.69 | 85.17 | -14.41 | |||||
Accounts Receivable, 2 Yr. CAGR % | - | - | - | - | - | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 89.91 | 18.77 | 36.22 | -10.61 | 10.57 | |||||
Total Assets, 2 Yr. CAGR % | 28.27 | 50.69 | -6.5 | -38.77 | -35.12 | |||||
Tangible Book Value, 2 Yr. CAGR % | 43.01 | 88.65 | -4.3 | -56.07 | -75.85 | |||||
Common Equity, 2 Yr. CAGR % | 27.96 | 48.22 | -8.57 | -46.17 | -66.5 | |||||
Cash From Operations, 2 Yr. CAGR % | 12.26 | 18.77 | 26.43 | 13.2 | -32.18 | |||||
Capital Expenditures, 2 Yr. CAGR % | -38.8 | 127.33 | 170.18 | -35.67 | -73.7 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 11.62 | 16.11 | 36.85 | 19.78 | -38.82 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 11.66 | 16.5 | 36.88 | 19.51 | -44.17 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 40.14 | 919.65 | 447.75 | 166.5 | -23.06 | |||||
Gross Profit, 3 Yr. CAGR % | 17.65 | 32.59 | -2.92 | 23.39 | -30.86 | |||||
EBITDA, 3 Yr. CAGR % | 18.38 | -10.01 | 5.44 | 25.23 | 10.74 | |||||
EBITA, 3 Yr. CAGR % | 18.27 | -10.43 | 5.57 | 25.29 | 11.54 | |||||
EBIT, 3 Yr. CAGR % | 18.27 | -10.43 | 5.57 | 25.29 | 11.54 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 17.69 | -11.26 | 5.67 | 24.73 | 17.09 | |||||
Net Income, 3 Yr. CAGR % | 17.69 | -11.26 | 5.67 | 24.73 | 17.09 | |||||
Normalized Net Income, 3 Yr. CAGR % | 16.96 | -10.96 | 5.91 | 24.73 | 17.09 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 4.9 | -19.79 | -2.6 | 21.27 | 17.03 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 108.25 | 91.06 | 10.61 | 15.62 | 5.46 | |||||
Total Assets, 3 Yr. CAGR % | 31.44 | 28.07 | 15.86 | -21.78 | -33.94 | |||||
Tangible Book Value, 3 Yr. CAGR % | 54.65 | 39.96 | 34.47 | -36.29 | -65.85 | |||||
Common Equity, 3 Yr. CAGR % | 30.93 | 23.42 | 16.95 | -30.7 | -56.61 | |||||
Cash From Operations, 3 Yr. CAGR % | 15.61 | 22.03 | 16.07 | 22.71 | -20.11 | |||||
Capital Expenditures, 3 Yr. CAGR % | 21.07 | -12.37 | 175.86 | -9.4 | -34.5 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 13.69 | 16.27 | 26.07 | 21.82 | -17.76 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 14.9 | 16.51 | 26.13 | 21.86 | -22.76 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | -36.39 | 131.46 | 254.63 | 96.06 | 202.76 | |||||
Gross Profit, 5 Yr. CAGR % | 29.66 | 31.45 | 10.05 | 17.81 | -10.06 | |||||
EBITDA, 5 Yr. CAGR % | 27.25 | 3.02 | 15.16 | 19.73 | -5.36 | |||||
EBITA, 5 Yr. CAGR % | 27.06 | 2.68 | 15.17 | 19.74 | -5.18 | |||||
EBIT, 5 Yr. CAGR % | 27.06 | 2.68 | 15.17 | 19.74 | -5.18 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 34.55 | 3.93 | 15.06 | 19.14 | -2.86 | |||||
Net Income, 5 Yr. CAGR % | 50.46 | 3.93 | 15.06 | 19.14 | -2.86 | |||||
Normalized Net Income, 5 Yr. CAGR % | 46.76 | 2.36 | 14.63 | 19.38 | -2.73 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 9.7 | -10.64 | 5.61 | 12.09 | -7.51 | |||||
Accounts Receivable, 5 Yr. CAGR % | - | - | 180.89 | - | - | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 41.99 | 66.68 | 75.73 | 41 | 10.59 | |||||
Total Assets, 5 Yr. CAGR % | 29.63 | 33.1 | 14.7 | -4.67 | -8.12 | |||||
Tangible Book Value, 5 Yr. CAGR % | 96.67 | 76.38 | 27.63 | -11.96 | -32.34 | |||||
Common Equity, 5 Yr. CAGR % | 30.47 | 30.91 | 13.41 | -11.44 | -29.07 | |||||
Cash From Operations, 5 Yr. CAGR % | 26.4 | 25.81 | 19.82 | 18.42 | -6.38 | |||||
Capital Expenditures, 5 Yr. CAGR % | - | 26.45 | 66.91 | -22.56 | 7.75 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 26.13 | 21.83 | 22.47 | 17.66 | -5.59 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 26.2 | 21.92 | 23.26 | 17.7 | -8.96 |
- Stock Market
- Equities
- IRLAB A Stock
- Financials IRLAB Therapeutics AB
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















